KDB94001
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
In brief: Merilog - a NovoLog biosimilar., PMID:40512611
CGM-Based Real-World Data on the Transition from Glargine U100 to U300 in Children and Adolescents with Type 1 Diabetes., PMID:40506022
Choice of Insulin Coformulations: Biphasic Insulin Versus Insulin-GlP1RA., PMID:40500836
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?, PMID:40497353
Impact of switching from neutral protamine hagedorn insulin (NPH) to glargine insulin on glycemic control and clinical outcomes in pediatric patients with type 1 diabetes., PMID:40491723
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial., PMID:40482670
Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec., PMID:40465144
Insulin-Induced Acanthosis Nigricans., PMID:40458329
Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England., PMID:40441739
Post-marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States: A disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) database., PMID:40437951
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE., PMID:40424051
When to Consider a Diagnosis of Maturity-Onset Diabetes of the Young: Precise Diagnosis Leads to Better Management and Quality of Life for the Patients., PMID:40395699
Evaluation of an Alternative Approach to Managing Diabetic Ketoacidosis: Combination Rapid-Acting and Basal Subcutaneous Insulin (CRABI-DKA)., PMID:40390456
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial., PMID:40388190
Hypoglycaemia as a cause of dynamic ECG changes: recognition and management., PMID:40379298
Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database., PMID:40356973
The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4., PMID:40354448
Multicenter, Phase 4 Clinical Study from India to Evaluate the Safety and Efficacy of Insulin Glargine 300 U/ml in Insulin-Naïve People with Type 2 Diabetes Uncontrolled on Oral Anti-hyperglycemic Drugs: SAFEGUARD Study., PMID:40338497
Investigation of new non-toxic inhibitors of fibril formation and preservatives for insulin preparations its analogues., PMID:40324845
Insulin/PHMB-grafted sodium alginate hydrogels improve infected wound healing by antibacterial-prompted macrophage inflammatory regulation., PMID:40319298
Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation., PMID:40314944
Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study., PMID:40309264
Effectiveness of the dual GIP/GLP1-agonist Tirzepatide in two cases of Alström syndrome, a rare obesity syndrome., PMID:40302276
Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study., PMID:40292754
Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature., PMID:40292250
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study., PMID:40288809
Pharmacokinetics, Pharmacodynamics, and Bioequivalence of Test Insulin Glargine Versus Reference Preparation (Lantus®) in Healthy Male Volunteers-By Euglycemic Clamp Technique., PMID:40284414
Analysis of Patient Education Guides Generated by ChatGPT and Gemini on Common Anti-diabetic Drugs: A Cross-Sectional Study., PMID:40276455
Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial., PMID:40267365
Clinical Management of Euglycemic Ketoacidosis in a Cat With Congenital Diabetes Mellitus Treated With Insulin and Dapagliflozin., PMID:40254974
An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability., PMID:40211481
Comparative Study of Efficacy and Safety of Dapagliflozin vs Basal Insulin in Stabilizing Glycemic Variability in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Triple Drug Combination Therapy., PMID:40200608
Timing of Insulin Glargine 300 U/ML: Does It Really Matter in Terms of Efficacy and Safety at Insulin Initiation?, PMID:40190894
The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5., PMID:40186685
State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar., PMID:40184059
Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies., PMID:40176458
Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine., PMID:40162894
A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa., PMID:40122825
Hypoglycemia Secondary to Intentional Insulin Poisoning Managed With Intravenous Hydrocortisone., PMID:40110567
Insulin glargine 300 U/mL safety data in pregnancy., PMID:40105254
Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study., PMID:40098261
Prescription patterns and the cost of antihyperglycemic drugs in patients with diabetes mellitus in Iran from 2014 to 2019., PMID:40096947
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme., PMID:40083081
Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study., PMID:40056372
Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database., PMID:40055991
An overview of insulin therapy for the non-specialist., PMID:40035222
Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial., PMID:40033680
What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups-Sharing Canadian perspectives., PMID:40013436
iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies., PMID:40013432
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
